The Food and Drugs Authority (FDA)
has cautioned the public against buying medicines from Tobinco
Pharmaceuticals Limited and their supplier, Bliss GVS Pharmaceuticals,
an Indian company, since there are doubts about the efficacy, safety and
quality of some of the drugs from the two companies.
The warning follows a revelation that
out of over 100 medicines imported and distributed by Tobinco, only
seven had been approved by the FDA.
Tobinco and Bliss GVS have both
written to appologise for the incident. They have also pledged, in two
seperate letters, against a recurrence of the unfortunate incident.
The letters, both dated September 26,
2013, was addressed to Dr. Stephen Opuni, Chief Executive of the FDA
shortly after the Bureau of National Investigation (BNI) picked up the
heads of the two companies for questioning over circumstances
surrounding the importation of the drugs.
A
press statement signed by the FDA boss, Dr. Opuni, admitted the receipt
of the two separate letters from the chairman of Tobinco, Mr. Samuel
Tobbin and the Managing Director of Bliss GVS Pharmaceuticals of India,
Mr.Shibroar Kamath, adding that the two companies would be assisting
with investigations.
One
of the fake drugs, Gsunate Plus, was imported into Ghana by Tobinco
Pharmaceuticals Ltd, and it is purported to be for the treatment of
malaria in children by administration through the anus.
However, samples of the drug ware found to be fake after tests were conducted on them by the FDA.
The FDA have however revealed that
drugs from Tobinco such as Nifin 20-R Tablets, Slipizem 2.5mg
Suppository, Slipizem 5mg Suppository, Lonart tablets, Lonart Forte
Tablets Lonart Oral Suspension and Ciprotab Tablets, have been approved
and hence could be purchased
No comments:
Post a Comment